Compile Data Set for Download or QSAR
Report error Found 824 of ki for UniProtKB: P08473
TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298285(US11547687, Example 2A | US11547687, Compound Exam...)
Affinity DataKi:  0.200nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298285(US11547687, Example 2A | US11547687, Compound Exam...)
Affinity DataKi:  0.200nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50411736(CHEMBL271225)
Affinity DataKi:  0.280nMAssay Description:Inhibition of human recombinant NEP by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/21/2013
Entry Details Article
PubMed
TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582848(US11547687, Comparative Compound J | US20230285340...)
Affinity DataKi:  0.316nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582847(US11547687, Comparative Compound I | US20230285340...)
Affinity DataKi:  0.316nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50614468(CHEMBL5272269)
Affinity DataKi:  0.400nMAssay Description:Binding affinity to neutral endopeptidase (unknown origin) assessed as inhibition constantMore data for this Ligand-Target Pair
In Depth
Date in BDB:
4/22/2024
Entry Details
PubMed
TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582849(US11547687, Comparative Compound K)
Affinity DataKi:  0.501nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM582848(US11547687, Comparative Compound J | US20230285340...)
Affinity DataKi:  0.501nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin/Angiotensin-converting enzyme(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298305(US11547687, Compound Example 5A | US10123984, Exam...)
Affinity DataKi:  0.631nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2023
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM617465(US20230285340, Example 5A)
Affinity DataKi:  0.631nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2023
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50407297(CHEMBL2052008)
Affinity DataKi:  0.700nMAssay Description:In vivo inhibitory potency against neutral endopeptidase by displacement of [3H]HACBOGly binding in mouse kidneyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50024101((S)-2-((S)-2-Mercaptomethyl-3-phenyl-propionylamin...)
Affinity DataKi:  0.700nMAssay Description:Inhibition of human recombinant NEP using Suc-Ala-Ala-Phe-AMC as substrate after 30 mins by fluorimetryMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/12/2015
Entry Details Article
PubMed
TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50407297(CHEMBL2052008)
Affinity DataKi:  0.700nMAssay Description:In vivo inhibitory potency against neutral endopeptidase by displacement of [3H]HACBOGly binding in mouse kidneyMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM50411731(CHEMBL257726)
Affinity DataKi:  0.800nMAssay Description:Inhibition of human recombinant NEP by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
5/21/2013
Entry Details Article
PubMed
TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299347(US9593110, Example 1 | (2S,4S)-5-(5′-Chloro-...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299348(US9593110, Example 53 | (2S,4S)-5-Biphenyl-4-yl-2-...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299353(US9593110, Example 17 | (2R,4R)-2-Amino-5-(3,5R...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299355(US9593110, Example 61a | US9593110, Example 74 | U...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299355(US9593110, Example 61a | US9593110, Example 74 | U...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299369(US9593110, Example 67 | (2R,4R)-5-(5′-Chloro...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299386(US9593110, Example 20 | (2S,4S)-2-Aminomethyl-5-(5...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299394(US9593110, Example 3 | (2S,4S)-5-(3′-Chlorob...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299445(US9593110, Example 70 | (2R,4R)-2-(6-Aminohexanoyl...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299466(US9593110, Example 71 | (2R,4R)-5-(5′-Chloro...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299493(US9593110, Example 5 | (2S,4S)-5-Biphenyl-4-yl-2-m...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299495(US9593110, Example 72 | (2R,4R)-2-(5-Amino-pentano...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299496(US9593110, Example 6 | (2S,4S)-5-(5′-Chloro-...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299498(US9593110, Example 73 | (2R,4R)-5-(5′-Chloro...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299628(US9593110, Example 80 | (2S,4S)-5-(3′-Bromob...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299630(US9593110, Example 81 | US9593110, Example 85a | (...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299633(US9593110, Example 8 | (2S,4S)-5-(3′-Chlorob...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299634(US9593110, Example 28 | (2S,4S)-2-(Acetylaminometh...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299635(US9593110, Example 29 | (2R,4R)-5-(5′-Chloro...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299630(US9593110, Example 81 | US9593110, Example 85a | (...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299630(US9593110, Example 81 | US9593110, Example 85a | (...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299630(US9593110, Example 81 | US9593110, Example 85a | (...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299639(US9593110, Example 10 | (2S,4S)-5-Biphenyl-4-yl-2-...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299643(US9593110, Example 13 | (2R,4R)-2-Amino-5-(5′...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299647(US9593110, Example 15 | (2R,4R)-2-Amino-5-(5′...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299651(US9593110, Example 33 | (2R,4R)-2-(2-Aminoacetylam...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299642(US9593110, Example 87b | US9593110, Example 88b | ...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM299662(US9593110, Example 40 | (2R,4R)-2-(4-Aminobutyryla...)
Affinity DataKi: <1nMAssay Description:Recombinant human NEP and recombinant human ACE were obtained commercially (R&D Systems, Minneapolis, Minn., catalog numbers 1182-ZN and 929-ZN, resp...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/14/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 824 total ) | Next | Last >>
Jump to: